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Introduction
The mechanism of carcinogenesis is not Definitions of nongenotoxic carcinogens are fully understood for any chemical, and not always consistent in the scientific literaknowledge of the mechanisms for nongeno-ture. A nongenotoxic chemical is a chemitoxic carcinogens is substantially less exten-cal that does not form DNA adducts, does sive than that for genotoxic carcinogens. not induce DNA repair, and is negative in in vitro or in vivo tests for mutagenicity. Some authors consider a chemical to be nongenotoxic if it is negative in most short-term assays. Thus, genotoxic agents produce chemical alterations in DNA directly, whereas nongenotoxic agents are thought to indirectly stimulate hyperplastic or neoplastic responses. However, this definition does not preclude the possibility that a chemical is both DNA reactive and stimulates cell proliferation.
Classification systems based on labeling chemicals as genotoxic or nongenotoxic and on presumed mechanisms of action for each class lead to ambiguous reconstructions of the carcinogenic process. One motivation for such classification is that nongenotoxic carcinogens are thought to be less hazardous to human health than are genotoxic carcinogens. This view is based on the assumption that nongenotoxic carcinogens act as tumor promoters and exhibit threshold tumor dose-responses, whereas genotoxic carcinogens act as tumor initiators and exhibit proportional responses at low doses. The rationale for this assumption is that, by analogy with ionizing radiation, a single molecule of a genotoxic agent could, in theory, react with a cell's DNA and produce heritable changes in the genome of the affected cell. If an altered gene is involved in cellular differentiation or replication, such heritable changes could result in tumors. In the absence of direct effects of a nongenotoxic agent on DNA, it is assumed that exposure to the chemical leads to production of another substance which stimulates tumor development. Therefore, a minimal dose of the nongenotoxic agent would be required to accumulate a sufficient amount of the proximate carcinogen in the target tissue to produce a response.
In this paper, tumor promotion is used as an operational term referring to the pleiotropic changes in cellular differentiation and proliferation occurring during the clonal expansion of previously initiated cells. Chemicals that effect such changes have been classified as tumor promoters. However, this does not necessarily mean that the chemical affects the carcinogenic process solely through such activities. For example, a strong tumor promoter may elicit weak or indirect genotoxicity and weak tumor-initiating activity.
Animal studies demonstrate that tumor promoters can cause cancer in the absence of an initiating agent, and the existence or absence of threshold dose-responses cannot be determined from current knowledge of carcinogenic mechanisms (1) . More important, the fact that several nonmutagenic carcinogens have been found to be carcinogenic in experimental animals as well as in humans (e.g., benzene, 2,3,7,8- tetrachlorodibenzo-p-dioxin [ (8) . An extensive literature base shows that tamoxifen forms DNA adducts in the livers of rats, mice, and hamsters (9, 10) ; it is activated to form DNA adducts by rat or human liver microsomes (11) ; it is dastogenic in human lymphoblastoid cells (12) ; and liver tumors in rats treated with tamoxifen have a high frequency of p53 mutations (13) . These genotoxic activities demonstrate that tamoxifen does not act simply as tumor promoter.
Cytotoxic Agents that Induce Regenerative Hyperplasia
The suggestion that cytotoxic agents may cause tumors due to chronic cell proliferation is based largely on the finding that some chemicals that do not appear to react with DNA cause cytotoxicity and regenerative hyperplasia in the same organ in which tumors develop after long-term chemical exposure (14) (15) (16) . It has been hypothesized that DNA is more sensitive to damage during cell division and that increased rates of cell replication increase the probability of converting endogenous DNA damage into mutations by reducing the time available for DNA repair.
In this review cell replication is synonymous with cell division. Chemically induced cell proliferation denotes an increase in the number of a specific type of cell in a treated animal due to an increased rate of cell division relative to the rate of cell loss. Replicative DNA synthesis commonly has been evaluated by measurement of the fraction of cells incorporating bromodeoxyuridine or tritiated thymidine into DNA during S-phase of the cell cycle (Sphase labeling index). It should be noted that the S-phase labeling index would not be identical to the cell division rate when replication of DNA does not progress to formation of two viable daughter cells.
The debates over how and to what extent cell proliferation influences the carcinogenicity of nongenotoxic chemicals are complicated by the fact that cell replication is an integral component of the carcinogenic process. Indeed, cell division can fix promutagenic DNA damage into heritable mutations, and cell replication occurs during the clonal expansion of premalignant cells. However, it has not been established that the carcinogenic outcome in most tissues is determined by the cell division rate (17) (18) (19) . The general view at an international symposium on cell proliferation and chemical carcinogenesis was that although cell replication is involved inextricably in the development of cancers, chemically enhanced cell division does not reliably predict carcinogenicity (20) .
Several factors influence the predictability of cell proliferation for carcinogenesis. These include a) consistency and specificity within a large database of chemical carcinogens and noncarcinogens; b) quantitative correspondence between the doseresponse curves for cell proliferation and tumor incidence under similar experimental conditions; and c) persistence of the proliferative response (21) . If sustained cell proliferation is the sole determinant of the carcinogenicity of nongenotoxic chemicals, then equivalent site-specific increases in cell division rate by different chemicals must produce the same tumor response. However, the available data are too sparse to either support or refute this hypothesis.
The importance of a sustained increase in S-phase DNA labeling is illustrated in studies of phenobarbital. Dietary administration of this drug produced a 4-to 5-fold increase in hepatic DNA synthesis in rats after 3 days of treatment, and this rate returned to control levels by day 5 (22) . However, this transient response was not sufficient to account for the promoting effect of phenobarbital because prolonged exposure (> 100 days) was required to promote 2-acetylaminofluorene-initiated liver lesions (23) .The long-term inhalation studies of tetranitromethane are also instructive with respect to the role of regenerative hyperplasia in chemical carcinogenicity. Tetranitromethane, which is mutagenic in Salmonella and induces chromosomal aberrations and sister chromatid exchanges in CHO cells, produced high incidences of benign and malignant lung neoplasms in both sexes of rats and mice at exposure concentrations ranging from 0.5 to 5 ppm (24) . These exposures also produced high incidences of hyperplasia of the respiratory epithelium in rats and mice without inducing tumors of the nasal cavity in either species. Thus, even for a potent mutagen and carcinogen, chronic irritation and regenerative hyperplasia are not predictive of a carcinogenic response.
Trihalomethanes
The induction of liver tumors in female mice treated with chloroform by gavage in corn oil was suggested to be due to cytotoxicity and regenerative hyperplasia resulting from the metabolism of this trihalomethane to a reactive toxic intermediate (25) . Both doses of chloroform used in the bioassay of this chemical caused centrilobular hepatocyte necrosis, increases in serum activities of the liver enzymes alanine aminotransferase and sorbitol dehydrogenase, and increases in replicative DNA synthesis in the liver.
A 2-year study in female mice exposed to chloroform at doses up to 1800 ppm in drinking water (a similar daily dose as the gavage study) did not induce liver tumors (26) . Because these doses did not cause hepatotoxicity or produce an increase in the S-phase labeling index, Larson et al. (25) suggested that the rate of oxidative metabolism of chloroform in the livers of these animals was insufficient to cause regenerative hyperplasia consequent to cytotoxicity. They concluded that lower oxidative rates in the drinking water study, leading to less cell replication, could explain the difference in the cancer responses by the two routes of exposure. Consistent with this hypothesis, the physiologically based pharmacokinetic (PBPK) model of Corley et al. (27) predicted the peak rates of metabolism of chloroform in the liver to be considerably higher in female mice given a single carcinogenic dose of chloroform by gavage than in mice exposed to a comparable daily dose in the drinking water.
Inhalation exposure of female mice to 30 ppm chloroform did not cause hepatocellular necrosis either, but unlike the drinking water exposure, it did produce a 7-fold increase in the hepatocyte labeling index relative to controls (28) . However, the rate of hepatic metabolism of chloroform predicted by the PBPK model in mice exposed to 30 ppm by inhalation was less than the predicted rate of metabolism in mice exposed to 1800 ppm chloroform in the drinking water U Robert Buchanan, personal communication). The inconsistency between the experimental data and model predictions for the drinking water and inhalation studies demonstrates that either liver metabolism of chloroform does not predict the cell replication rate or the PBPK model is incorrect.
Mutagenicity was not considered to be an important contributing factor in the carcinogenicity of chloroform because the results of the majority of genotoxicity studies on this chemical were negative. Rosenthal (29) contends that there is some evidence of genotoxicity due to chloroform and that many of the short-term tests on this chemical were inconclusive. Chloroform induced sister chromatid exchanges in human lymphocytes in vitro and in mouse bone marrow cells in vivo (30) , gene conversion and mitotic crossover in Saccharomyces cerevisiae (31), and elicited low-level binding to calf thymus DNA in the presence of rat liver microsomes (32) .
Trihalomethanes as a class are metabolized by a microsomal cytochrome P450-dependent monooxygenase to reactive dihalocarbonyl intermediates (33) . The hepatotoxicity of chloroform appears to be related to its metabolism, presumably due to the covalent binding of its metabolite phosgene to cellular macromolecules, leading to cell death (34, 35) . Pretreatment of rats with phenobarbital enhanced the metabolism and the hepatotoxicity of chloroform, while cysteine treatment was protective against chloroform-induced hepatocellular necrosis.
Because of the large energy difference between C-Br (54 kcal/mol) and C-Cl (78 kcal/mol) bonds (36) , bromodichloromethane (BDCM) should be almost exclusively metabolized to the same dihalocarbonyl as that formed from chloroform. Thus, it might be expected that the toxicological effects of BDCM would mimic those of chloroform. When the doses of chloroform, BDCM, or chlorodibromomethane (CDBM) used in the carcinogenicity studies of these trihalomethanes were expressed as mol/kg/day, a composite dose-response plot for liver neoplasms produced in female B6C3F1 mice by these three chemicals revealed a relationship suggestive of a possible common mechanism of tumor induction (37) . Neither BDCM nor CDBM caused hepatocellular necrosis in the 2-year studies or in the 13-week studies at considerably higher doses. Thornton-Manning et al. (38) confirmed the lack of histopathological changes in the livers of female mice exposed to doses of BDCM that produced high incidences of liver tumors in the 2-year study of this chemical.Thus, overt toxicity followed by regenerative hyperplasia is not the sole determinant of the liver tumor response for this group of chemicals. The elucidation of the mechanisms of tumor development by cytotoxic chemicals requires much greater knowledge than that which can be obtained from measurements of S-phase labeling alone.
Inducers of X2-Microglobulin Nephropathy and Kidy Cancer in Male Rats
The current hypothesis on the role of aX21 in chemically induced kidney cancer is based on the observed accumulation of protein droplets containing aX2P in epithelial cells of the proximal convoluted tubules of male rats exposed to hydrocarbons that have been reported to cause kidney cancer in male rats after long-term exposure. tX2P is a low molecular weight protein (18.7 kDa) synthesized in the liver of male rats under androgenic control (39) . It is not synthesized by hepatocytes of female rats, mice of either sex, or several other species including humans. Hydrocarbons or their metabolites that bind reversibly to x21 do not increase the level of hepatic synthesis of this protein (40) . a2-Microglobulin is secreted into the blood, filtered through the glomerulus, and partially reabsorbed (50%) by endocytosis into proximal tubule epithelial cells of the P2 segment (41) . The unabsorbed fraction is excreted in the urine while the reabsorbed portion is presumably hydrolyzed to amino acids after fusion of endocytotic vesicles with epithelial cell lysosomes. The accumulation of protein droplets containing aX2P was suggested to be due to reversible binding of xenobiotic ligands to this protein, rendering it more resistant to proteolytic degradation (42, 43) .
The accumulation of a2P is hypothesized to cause lysosomal dysfunction resulting in cell killing (42) . The actual cause of cell death is not known. Sloughing of necrotic epithelial cells into the tubule lumen has been observed, and granular casts of necrotic cellular debris accumulate at the junction of the P3 segment of the proximal tubule and the thin loop of Henle. Regenerative proliferation of epithelial cells in the P2 segment occurs in response to the cell loss (44) (45) (46) .
Although the mechanistic link between cell proliferation and kidney cancer is unknown, it has been suggested that regenerative hyperplasia causes the tumorigenic response in the male rat kidney by increasing the likelihood of fixing presumed spontaneous cancer-initiating DNA damage into heritable mutations or by promoting the clonal expansion of spontaneously initiated cells (46, 47 (61) . There is no adequate database relating level of cell proliferation to renal tumor response in male rats (57) . TMP, the model compound upon which the hypothesis linking a2i accumulation with kidney cancer in the male rat is based, did not produce kidney tumors in male rats after lifetime exposure (Cesare Maltoni, personal communication).
An Alternative Hypothesis. The physiological function of a21P is unknown.
Because hydrophobic chemicals bind to this protein, it may serve as a carrier for the urinary excretion of pheromones or other lipophilic ligands. In the liver of male rats where this protein is synthesized, intermediary metabolites of certain nephrotoxic agents may bind to a2p and thereby be shielded from activating and detoxicating reactions (57) . The ct2p-ligand complex is then transported to the kidney. In female rats there is a greater tendency to form conjugated products of TMP metabolites (54) (67, 68) . However, DEHP but not DEHA gave a positive liver tumor response in the 2-year studies in rats (67, 68 Genotoxicity. Peroxisome proliferators, for the most part, lack genotoxic activity. However, when a consistent genotoxic effect is detected for a specific peroxisome proliferator, then that activity cannot be dismissed as unimportant in the carcinogenic process. For example, Wy-14,643, a potent peroxisome proliferator, induced sister chromatid exchanges and micronuclei formation in primary cultures of both rat and human hepatocytes (71) , and several peroxisome proliferators induce morphological transformation of Syrian hamster embryo cells (72) . Nafenopin and ciprofibrate, but not DEHA, induced sister chromatid exchanges, chromosomal aberrations, and micronuclei in rat hepatocytes (73) . Thus, the combination of clastogenicity and/or cell-transforming activity and peroxisomal enzyme induction may contribute to the carcinogenicity of several of the peroxisome proliferators. Hegi et al. (74) reported that the frequency and spectrum of ras gene mutations observed in ciprofibrate-induced liver tumors were different from that in spontaneous liver tumors, indicating that this peroxisome proliferator does not act simply by promoting spontaneous preneoplastic lesions in mice.
Oxidative Stress. The peroxisomal oxidation system has received much attention regarding the mechanism of hepatotoxicity of peroxisome proliferators because the initial step catalyzed by fatty acyl-CoA oxidase produces H202 by electron transfer to oxygen. In the livers of rats or mice treated with peroxisome proliferators, fatty acylCoA oxidase activity is increased 5-to 20-fold, whereas catalase activity is increased by less than 2-fold. Thus, Reddy and Lalwani (75) proposed that the imbalance between production and degradation of H202 due to enhanced peroxisomal oxidation could lead to an increase in H202-mediated oxidative damage and carcinogenesis. Increased levels of hydroxyl radical generated from H202 may produce tumors due to reactivity of this oxidant with DNA.
In support of this hypothesis, Rao et al. (76) (23) . The finding that enzyme-altered hepatic foci were not induced in rats fed Wy-14,643 for 3 weeks followed by partial hepatectomy (87) (aryl hydrocarbon) receptor. The activated Ah receptor forms a heterodimer with another transcription factor (Ah receptor nuclear translocator, arnt), and this ternary complex binds to regulatory sequences on DNA and alters the expression of several proteins (95) . Some of these proteins may be involved in the carcinogenic response. It has been suggested (96) that the doseresponse curve for tumor incidence consequent to exposure to TCDD may show appreciable sigmoidicity, owing to insufficient occupancy of the Ah receptor at low doses. In that case, TCDD-induced cancers might exhibit a threshold below which no effects of dioxin would occur (97) . The large amount of data available on responses of laboratory animals to treatment with dioxin provides an opportunity to test the hypotheses that TCDD is purely a tumor promoter and that the Ah receptormediated tumor dose-response exhibits threshold behavior.
In order to identify conditions under which threshold responses to TCDD are possible, several PBPK models of its disposition in the rat have been constructed (e.g., 98, 99) . These models include absorption of TCDD from the gut, its distribution to tissues, its metabolic clearance from the liver, and alterations in the concentrations of several hepatic proteins which are candidates for biomarkers of TCDD's effects. The rates of induction of the proteins were assumed to follow saturation kinetics with respect to the concentration of the Ah-TCDD complex. A doseresponse curve whose slope approaches zero as the dose approaches zero was assumed to be evidence of a threshold. Such behavior might provide a rationale for deviating from linear extrapolations of cancer risk from low-dose TCDD exposures. The following discussion is based on the PBPK model of Kohn et al. (98) , as it is the only one of the existing TCDD models to extend beyond dosimetry and propose carcinogenic mechanisms.
Enzyme Induction. The model of Kohn et al. reproduced the measured concentrations of dioxin in the liver and blood after 31 weeks of biweekly oral dosing with TCDD (100) and matched the liver and fat concentrations for a number of other dosing scenarios. The model also reproduced the observed hepatic concentrations of cytochromes P4501A1 and P4501A2 (CYPlAl and CYP1A2) and the Ah, estrogen, and epidermal growth factor (EGF) receptors after 31 weeks of exposure. The computed response of each of these proteins was proportional to administered TCDD at dose rates up to 10 ng/kg/day. Because CYPlAI is constitutively expressed in liver only at very low levels and TCDD induces this protein by about 200-fold, this response is a good biomarker of dioxin exposure. The proportional response of CYPlAI at low doses argues against the existence of a threshold for effects mediated by the Ah receptor. Allowing for sigmoidicity in the rate of expression of this protein, which would produce a threshold response, did not improve the fit to the data. This indicates that sigmoidal kinetics is not required to reproduce the observed dose-response.
When data on CYPlAl mRNA levels in TCDD-treated rats became available (101), the model was extended to include two steps in expression: transcription of the gene and translation of the message into protein (102) . Several mechanistic models were compared with the experimental data (101) . The model which best fit the data included high-affinity and low-affinity binding sites for the Ah-TCDD-arnt complex; occupancy of both sites was required for transcriptional activation of the CYPIAI gene. The model predicted a response of message production that was sublinear at low doses and a response of protein synthesis that was supralinear at low message level, indicating that the proportional expression of CYPIAI is the net response of these two processes. These results show that a threshold response is not an inevitable result of a receptor-mediated mechanism. Even if the initial response does show a threshold, subsequent events leading to the final outcome can compensate for this sublinearity.
It could be argued that the computed behavior for CYPlAl induction is an artifact of the choice of model specification; a different mathematical representation may lead to a different predicted dose-response. The model of Kohn et al. (98) included the increase in ligand binding capacity of the hepatic Ah receptor observed with increasing dose of dioxin (103) . Because dioxin increases the Ah receptor binding capacity in liver, the concentration of the Ah-TCDD complex is predicted to rise more rapidly with dose than would be predicted by models that neglect this effect. The PBPK model of Andersen et al. (99) ignored this effect and found that sigmoidal kinetics best described the relationship between the concentration of the Ah-TCDD complex and the observed production of CYPlAI. Sigmoidal kinetics predicts a steeper rise in protein production with increasing dose than does a model with hyperbolic response, and such steep kinetics imitates the effect of increases in Ah receptor binding capacity. Models that do not represent all of the pertinent biological events may give unreliable results.
Induction of a Growth Factor.
Because there is no evidence that CYPlAI is involved in the carcinogenic action of TCDD, the hypothesis that production of liver tumors in female rats by TCDD is due to promotion mediated by an induced hepatic growth factor was examined with the model. TCDD down-regulates the hepatic plasma membrane EGF receptor without altering the transcription of its gene into mRNA in vivo (104) . Binding of peptide ligand to the EGF receptor causes its internalization. The internalized receptor's tyrosine kinase activity initiates a cascade of events leading to increased cell replication (105) .
The liver does not produce EGF, but it does produce transforming growth factor-a (TGF-a), another ligand of the EGF receptor (106) . This peptide was treated as the induced growth factor in the model of Kohn et al. (98) . TCDD induces TGF-a in tissues such as keratinocytes (107) Increases in UGT-1 mRNA and alterations in T4 and TSH as described above have been observed in rats given biweekly oral doses of TCDD for 31 weeks (115) . Such treatment results in increased serum TSH levels and in concomitant hypertrophy of thyroid follicular cells and thyroid hyperplasia (115) . Other Ah agonists have similar effects as dioxin (116, 117) . Goitro A threshold for a response to a carcinogen has been defined in absolute biological terms as the dose below which no response occurs. In practice, an apparent threshold is detected statistically as that dose below which the activity of a biomarker for the response in treated subjects is indistinguishable from that in controls. However, attribution of a threshold in such circumstances may be an artifact. Because of measurement errors and interindividual variability, it is always possible to find a dose which satisfies this criterion even for genotoxic chemicals, which have been assumed to exhibit linear cancer doseresponses. The more sensitive and repeatable is the measurement of the biomarker, the lower such an apparent threshold would seem. Thus, categorization of a response as exhibiting a threshold is limited by the nature of the end point being measured and by the accuracy of that measurement. Assessment of risks of adverse health effects consequent to exposure to a chemical should be based on the shape of the dose-response curve obtained from experimental data by the best available mathematical techniques.
Mechanistic studies in chemical carcinogenesis have greatly added to our understanding of the steps involved in the carcinogenic process. However, there is still much uncertainty on the nature of the complex interacting processes that occur between exposure to nongenotoxic carcinogens and tumor development. Use of mechanistic data in risk assessments requires scientific judgment and should not rely on overly speculative hypotheses. The application of new research findings to public health decisions should proceed with caution to ensure adequate validation and proper interpretation of the data. Several critical questions must be examined.
Is the mechanism biologically plausible? Are the data of sufficient quality to reasonably link the specific mechanistic process to the cancer outcome?
Are competing explanations valid? Is the particular mechanism (mode of action) the determinant of the carcinogenic effect or are multiple processes possibly involved?
Over-simplified classification systems add uncertainty and inaccuracy to evaluations of human risk. Evaluations of carcinogenicity by chemicals that act via "nongenotoxic" mechanisms should not be limited to promotion nor should the response be assumed to exhibit a threshold. Cancer is a complex multistep process and chemicals may affect the carcinogenic outcome by producing changes that affect one or several steps.
Research is needed to identify the multiple factors that contribute to the carcinogenicity of both genotoxic and nongenotoxic carcinogens and to quantify their contributions to the cancer dose-response curve. Integrating this information into cancer dose-response models would permit prediction of the shape of the doseresponse curve instead of having to rely on default assumptions. Such an approach should provide a more realistic, hence more credible, means of estimating human low-dose risk. Until a better understanding of the mechanistic processes involved in the carcinogenic response is available, the prudent policy for protecting public health is the one that considers the dose-response of all potential contributing effects of each specific chemical.
